EGFR and lung carcinoma: Interestingly, we found that the combination of nutlin‐3 or carfilzomib and osimertinib (3rd‐generation inhibitors of EGFR T790M) were highly effective in EGFR T790M lung cancer cell line NCI‐H1975 (Fig. S5).